SCHEDULE 13G/A: Armistice Capital Discloses 4.99% Passive Stake in Senti Biosciences
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in Senti Biosciences, Inc.'s Class A Common Stock as of March 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 1,439,812 shares of Senti Biosciences, Inc.'s Class A Common Stock.
- This ownership represents 4.99% of the total outstanding Class A Common Stock.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment intent.
- Armistice Capital, LLC, as the investment manager, and Steven Boyd, as its managing member, exercise shared voting and dispositive power over these shares.
- The direct holder of the shares is Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital, LLC.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information to assess positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant, but non-controlling, passive investment by an institutional investor in a publicly traded company. It does not provide information related to broader industry trends or competitive landscape.
Related Party Transactions
- Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, LLC, is the direct holder of the reported securities and has the right to receive dividends and proceeds from their sale.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional investor's stake provides transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the Joint Filing Statement pursuant to Rule 13d-1(k). |
| 03/31/2025 | Date of the event which required the filing of this statement (beneficial ownership position). |
| 05/15/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Senti Biosciences, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Class A Common Stock, SEC Filing, Investment Management, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.